—Among adults, coverage and preventable burdens were lowest for pneumococcal conjugate vaccine (PCV) 15 and highest for PCV31, with PCV21 preventing notable burdens of both acute respiratory ...

The increase in invasive pneumococcal disease across Europe is driven by Streptococcus pneumoniae, which also causes pneumonia and acute otitis media that can progress to invasive infections. Nearly ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Vaccine uptake data have been examined to assess the impact of moving from a "2+1" to a "1+1" Pneumococcal Conjugate Vaccine (PCV) dose schedule on vaccine coverage and health inequalities among ...

Vaxcyte is positioned to disrupt the pneumococcal vaccine market with its engineered VAX-31, overcoming carrier suppression limitations faced by incumbents. PCVX's $2.7B cash position supports an ...